Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention is directed to the administration to a warm blooded animal including humans of the combination of tegafur, uracil, and folinic acid and its administration with cyclophosphamide for the treatment of tumors.
BACKGROUND OF THE INVENTION
5--Fluorouracil
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This invention relates to an improved treatment for cancer comprising administering a combination of at least one camptothecin derivative and at least one other colorectal anticancer drug. More specifically, the invention relates to treatments for colorectal cancer comprising administering a
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This invention relates to an improved treatment for cancer comprising administering a combination of at least one camptothecin derivative and at least one other colorectal anticancer drug. More specifically, the invention relates to treatments for colorectal cancer comprising administering a
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention is directed to an oral dosage form for administration to a warm blooded animal of the combination of tegafur, uracil, and folinic acid to potentiate coadministered oxaliplatin for the treatment of tumors.
BACKGROUND OF THE INVENTION
5-Fluorouracil (5-FU)
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD
The present invention relates to pharmaceutical compositions for the treatment of cancer. In particular, the present invention relates to compositions comprising 5-fluorouracil, cyclodextrin and folinic acid and their use in the treatment of cancer.
BACKGROUND OF THE
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE DISCLOSURE
Serine catabolism is initiated by serine hydroxymethyltransferase (SHMT) activity, catalyzed in the cytosol by SHMT1 and in the mitochondria by SHMT2. SHMTs catalyze a reversible reaction converting serine to glycine, with concurrent methylene-tetrahydrofolate (THF)
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
CROSS REFERENCE TO RELATED APPLICATION
This application is a 35 USC .sctn.371 National Phase Entry Application from PCT/JP2004/003189, filed Mar. 11, 2004, and designating the U.S.
TECHNICAL FIELD
The present invention relates to an antitumor effect potentiator and an antitumor agent.
BACKGROUND
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD
The present invention relates to an antitumor effect potentiator and an antitumor agent.
BACKGROUND ART
The research and development of antitumor agents has been actively pursued. A variety of effective antitumor agents are clinically used in the treatment of malignant tumors.
For
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama. * Visa informacija pagrįsta paskelbtais moksliniais tyrimais